Morgans Financial Limited Interviews CEO Steven Lydeamore
Brisbane, Mar 29, 2019 AEST (ABN Newswire) - While in Brisbane this week, Anatara Lifesciences CEO Steve Lydeamore (
ASX:ANR) sat down with Scott Power, Senior Analyst at Morgans Financial Limited, Australia's largest national full-service retail stockbroking and wealth management network.
Steve spoke with Scott about the Company's plans in human gastrointestinal health; developing its unique natural dietary supplement to help Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD) patients.
Following on from the Company's successful in vitro proof of concept studies, Anatara will now move its Gastrointestinal ReProgramming dietary supplement into the final stage of pre-clinical development for IBD with mouse studies expected to be completed by end of July 2019. In parallel, the Company will commence planning for a human observational study for IBS, with patient recruitment anticipated to start in the second half of 2019.
To view Scott's interview with Steve, please visit:
http://www.abnnewswire.net/lnk/ZXHRST67
To view latest Corporate Fact Sheet, please visit:
http://abnnewswire.net/lnk/G465OU6A
About Anatara Lifesciences Limited
Anatara Lifesciences Limited (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing productsfor human and animal health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.
| ||
|
